Drug Development RFP
Forecasted
The Drug Development RFP from the Alzheimer's Drug Discovery Foundation funds innovative preclinical and early clinical research targeting new therapies for Alzheimer's and related dementias.
Browse similar grants
Funder: Alzheimer's Drug Discovery Foundation
Due Dates (Anticipated): September 2026 (Letter of Intent) | November 2026 (Invited Full Proposal)
Funding Amounts: Up to $5,000,000 per award; multi-year, milestone-based direct cost funding.
Summary: Supports IND-enabling studies and early-phase clinical trials for Alzheimer's and related dementias, prioritizing novel drug mechanisms and combination therapies.
Description
This opportunity from the Alzheimer's Drug Discovery Foundation (ADDF) aims to accelerate the development of innovative therapies for Alzheimer's disease and related dementias. Funding is provided for investigational new drug (IND)-enabling studies and early-phase clinical trials, from Phase 0 microdosing through Phase 2a proof-of-concept. The program prioritizes projects exploring novel drug mechanisms rooted in the biology of aging and neurodegeneration, as well as combination therapies and emerging therapeutic modalities. Both pharmacological interventions and devices are eligible, with an emphasis on disease-modifying and symptomatic agents that address critical gaps in current dementia treatment strategies.
